Cargando…
Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
We have evaluated the prognostic value of tumour-associated trypsin inhibitor (TATI) in stage III or IV ovarian cancer. Tumour-associated trypsin inhibitor (TATI) and CA 125 were determined in serum samples from 66 patients taken before primary surgery. TATI was elevated (> 22 micrograms l-1) in...
Autores principales: | Venesmaa, P., Lehtovirta, P., Stenman, U. H., Leminen, A., Forss, M., Ylikorkala, O. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033663/ https://www.ncbi.nlm.nih.gov/pubmed/7981075 |
Ejemplares similares
-
Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
por: Halila, H., et al.
Publicado: (1988) -
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
por: Halila, H., et al.
Publicado: (1987) -
Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990) -
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.
por: Haglund, C., et al.
Publicado: (1986) -
TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
por: Medl, M., et al.
Publicado: (1995)